Verve Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Verve Therapeutics, Inc. | VERV - NASDAQ |
$16.00-$18.00 | $19.00 | $30.00 | 14.035 million | 6/17/2021 |
| JP Morgan, Jefferies, Guggenheim Securities, William Blair | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-05-28 Terms Added 2021-06-14 | ||||||
Verve Therapeutics, Inc. Quote & Chart - Click for current quote - VERV
IPO Boutique aggregates information on public companies and private companies, such as "VERV" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Verve Therapeutics, Inc. (adapted from Verve Therapeutics, Inc. prospectus):
They are a genetic medicines company pioneering a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a genetic medicines company pioneering a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "VERV" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.